A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to to evaluate the efficacy and safety of Cavosonstat administered twice daily compared with Placebo for 24 Weeks in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)
Detailed Description:To investigate the effect of cavosonstat compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over 24 weeks of treatment.
To investigate:
The effect of cavosonstat compared with placebo, on the duration from baseline to first moderate AECOPD event
The effect of cavosonstat compared with placebo, on respiratory function, as assessed by post-bronchodilator percent-predicted forced expiratory volume in one second (ppFEV1)
The effect of cavosonstat compared with placebo on annualized rate of moderate AECOPD over 24 weeks of treatment
The effect of cavosonstat compared with placebo on annualized rate of severe AECOPD over 24 weeks of treatment
The safety and tolerability of cavosonstat compared with placebo
The pharmacokinetics of cavosonstat
Assessment of quality of life
100 项与 GSNOR Therapeutics, Inc. 相关的临床结果
0 项与 GSNOR Therapeutics, Inc. 相关的专利（医药）
100 项与 GSNOR Therapeutics, Inc. 相关的药物交易
100 项与 GSNOR Therapeutics, Inc. 相关的转化医学
